Page 139 - 《中国药房》2025年13期
P. 139
年美国FDA加速批准了Pola-BR用于治疗r/r DLBCL成 notherapy in relapsed or refractory diffuse large B-cell
人患者。2022 年美国血液学学会公布的 GO29365 研究 lymphoma:the ORCHARRD study[J]. J Clin Oncol,
终期 5 年的随访分析结果显示,Pola-BR 方案可为 r/r 2017,35(5):544-551.
®
DLBCL 患者带来 OS 持久获益,且无新增不良反应报 [ 6 ] Food and Drug Administration. GAZYVA(obinutuzumab)
[35]
道 。此外,除了Pola-BR方案,维泊妥珠单抗联合利妥 injection,for intravenous infusion[EB/OL]. [2025-01-10].
昔单抗、吉西他滨和奥沙利铂(Pola-R-GemOx)治疗 r/r https://www.accessdata.fda.gov/scripts/cder/daf/index.
cfm.
DLBCL 也具有良好疗效。一项Ⅲ期临床试验——
[ 7 ] SEHN L H,MARTELLI M,TRNĚNÝ M,et al. A randomi-
POLARGO 研究(NCT04182204)的初步结果表明,Pola-
zed,open-label,Phase Ⅲ study of obinutuzumab or rituxi-
R-GemOx 方案治疗 r/r DLBCL 患者的 ORR 和 CR 率分
mab plus CHOP in patients with previously untreated dif‐
别为40%、27%,血小板和中性粒细胞减少症是最常见的
fuse large B-Cell lymphoma:final analysis of GOYA[J]. J
[36]
AEs,但未发生5级或导致停药的AEs 。
Hematol Oncol,2020,13(1):71.
4 结语
[ 8 ] WANG K M,WEI G Q,LIU D L. CD19:a biomarker for
r/r DLBCL的治疗一直是临床面对的棘手问题。近
B cell development,lymphoma diagnosis and therapy[J].
年来随着研究者在抗体药物结构上的创新,增强了其免 Exp Hematol Oncol,2012,1(1):36.
疫杀伤力和靶向细胞毒性。近年来已被批准上市的单 [ 9 ] DUELL J,ABRISQUETA P,ANDRE M,et al. Ta‐
抗药物坦昔妥单抗,双抗药物奥尼妥单抗、格菲妥单抗、 fasitamab for patients with relapsed or refractory diffuse
艾可瑞妥单抗,ADC 药物维泊妥珠单抗、泰朗妥昔单抗 large B-cell lymphoma:final 5-year efficacy and safety
等均对 r/r DLBCL 患者人群显示出较高的 ORR 和 CR findings in the phase Ⅱ L-MIND study[J]. Haemato‐
率,为患者提供了更多选择。然而,抗体药物在临床应 logica,2024,109(2):553-566.
用中仍面临诸多挑战,如治疗安全性、患者耐受性等。 [10] BARCLAY A N,VAN DEN BERG T K. The interaction
目前正在进行的多项大规模、多中心临床试验正在探索 between signal regulatory protein alpha (SIRPα) and
这些药物的联合化疗方式、最佳使用剂量以及如何减少 CD47:structure,function,and therapeutic target[J]. Annu
治疗相关毒性,以提高患者的耐受性和长期生存率。综 Rev Immunol,2014,32:25-50.
上所述,抗体药物在r/r DLBCL治疗中展现出巨大潜力, [11] MAAKARON J,ASCH A S,POPPLEWELL L L,et al.
但仍需进一步研究和临床验证,以优化治疗策略,为患 Magrolimab in combination with rituximab+chemo‐
者带来更好的预后。 therapy in patients with relapsed or refractory (R/R) dif‐
参考文献 fuse large B-cell lymphoma (DLBCL)[J]. Blood,2022,
140(Suppl. 1):3728-3730.
[ 1 ] TERAS L R,DESANTIS C E,CERHAN J R,et al. 2016
[12] Gilead to discontinue phase 3 ENHANCE study of magro‐
US lymphoid malignancy statistics by World Health Orga‐
limab plus azacitidine in higher-risk MDS:2023[EB/OL].
nization subtypes[J]. CA Cancer J Clin,2016,66(6):
[2025-01-10]. https://www.gilead.com/news/news-details/
443-459.
2023/gilead-to-discontinue-phase-3-enhance-study-of-
[ 2 ] HITZ F,CONNORS J M,GASCOYNE R D,et al. Out‐
come of patients with primary refractory diffuse large B magrolimab-plus-azacitidine-in-higher-risk-mds.
cell lymphoma after R-CHOP treatment[J]. Ann Hematol, [13] FALCHI L,VARDHANA S A,SALLES G A. Bispecific
2015,94(11):1839-1843. antibodies for the treatment of B-cell lymphoma:promi-
[ 3 ] MATTIOLA I,MANTOVANI A,LOCATI M. The te- ses,unknowns,and opportunities[J]. Blood,2023,141
traspan MS4A family in homeostasis,immunity,and di- (5):467-480.
sease[J]. Trends Immunol,2021,42(9):764-781. [14] BARTLETT N L,ASSOULINE S,GIRI P,et al. Mosu‐
[ 4 ] THIRUVENGADAM S K,HUNTER B,VARNAVSKI A, netuzumab monotherapy is active and tolerable in patients
et al. Ofatumumab,etoposide,and cytarabine intensive with relapsed/refractory diffuse large B-cell lymphoma[J].
mobilization regimen in patients with high-risk relapsed/ Blood Adv,2023,7(17):4926-4935.
refractory diffuse large B-cell lymphoma undergoing au‐ [15] BUDDE L E,OLSZEWSKI A J,ASSOULINE S,et al.
tologous stem cell transplantation[J]. Clin Lymphoma Mosunetuzumab with polatuzumab vedotin in relapsed or
Myeloma Leuk,2021,21(4):246-256.e2. refractory aggressive large B cell lymphoma:a phase 1b/2
[ 5 ] VAN IMHOFF G W,MCMILLAN A,MATASAR M J, trial[J]. Nat Med,2024,30(1):229-239.
et al. Ofatumumab versus rituximab salvage chemoimmu‐ [16] DICKINSON M J,CARLO-STELLA C,MORSCHHAUSER
中国药房 2025年第36卷第13期 China Pharmacy 2025 Vol. 36 No. 13 · 1681 ·